News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BG Medicine Announces Important New Galectin-3 Findings Presented at American College of Cardiology's 61st Annual Scientific Session & Expo


3/26/2012 10:22:58 AM

WALTHAM, Mass., March 26, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today the results of several new studies related to the galectin-3 protein. BG Medicine markets a blood test for galectin-3 called the BGM Galectin-3 test for heart failure, which was cleared by the FDA in 2010 and obtained the CE mark for commercialization in the EU. The findings from the studies were presented at a symposium held on Sunday, March 25th at the American College of Cardiology's 61st Annual Scientific Session & Expo. The symposium was sponsored by BG Medicine. In conjunction with these events, the company will host a conference call and webcast this morning at 8:45 a.m. Eastern Time. A summary of the presentations and results is listed below.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES